HTHitoshi Takagi

Hitoshi Takagi

*This is an algorithmically generated author record based on publicly available information.

Hitoshi Takagi has a total of 231 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 December 2015
      • p. 663-7

    [Significance of zinc in hepatitis C].

    by Hitoshi Takagi, Daichi Takizawa, Kazuhisa Yuasa, Hideyuki Suzuki, Atsushi Naganuma, Takeaki Nagamine

  • Randomized controlled trial of epirubicin and miriplatin using together with TACE for hepatocellular carcinoma

    by Atsushi Naganuma, Takashi Hoshino, Hitoshi Takagi, Ken Sato, Satoru Kakizaki, Masanobu Yamada

    Background: The efficacy and safety of anticancer agents using for transcatheter arterial chemoembolization (TACE) to hepatocellular carcinoma(HCC) have not been evaluated.


  • Two Cases of Total Blindness and Hydrocephalus Caused by Carcinomatous Meningitis of Gastric Cancer

    by Atsushi Naganuma, Sanae Uehara, Eri Hayashi, Takashi Hoshino, Tomohiro Kudo, Hitoshi Takagi, Hiroshi Ishihara, Kouji Ishiguro, Toshiyuki Tanaka, Takaaki Yoshida

    Background: Patients of gastric cancer with meningeal carcinomatosis may suddenly get worse and urgent medical treatment may be needed. Two didactic cases are presented. Case: Case 1 was a 48 years old woman was admitted with headache, neck pain, nausea, transient unconsciousness and liver dysfunction. Thickened gastric wall, lower bile duct stenosis was demonstrated by CT. Magnetic resonance imaging of brain showed dilated cerebral ventricle. Type 4 gastric cancer was found out by upper gastrointestinal endoscopy. Lumbar spinal puncture showed elevated cerebrospinal fluid pressure and malignant cells. Hydrocephalus and visual impairment got worse rapidly and she died on the 3rd hospital day by central respiratory failure. Case 2 was a 46 years old woman. After the surgical treatment for the gastric cancer, six courses of the combination chemotherapy of S-1 plus cisplatinum were performed as adjuvant chemotherapy. The chemotherapy could not withhold the progression and metastases to ovary and lymph nodes developed. Meningeal carcinomatosis developed and induced total blindness and hydrocephalus. To improve the cerebrospinal fluid pressure and meningeal carcinomatosis, intrathecal chemotherapy was initiated using Ommaya reservoir. She survived two months and finally died of respiratory failure. Discussion: Since the hydrocephalus accompanied by gastric cancer with meningeal carcinomatosis usually progress rapidly, prompt ventricular drainage is useful and mandatory to overcome oncology emergency such as progressive hydrocephalus with total blindness and respiratory failure.

  • A case of Budd-Chiari syndrome that died of hepatic failure by gradual thromboses of hepatic veins

    by Erina Yuasa, Atsushi Naganuma, Takashi Hoshino, Eri Hayashi, Tsuyoshi Ogashiwa, Sanae Uehara, Naomi Miyamae, Tomohiro Kudo, Hitoshi Takagi, Hiroshi Ishihara, et al.

    症例は35歳女性.平成22年より非B非C型肝硬変として近医に通院しており,平成23年8月CTにて下大静脈と右・中肝静脈の閉塞所見を指摘された.平成24年1月より発熱,嘔気,腹部膨満が出現し,前述のCT所見に加え左肝静脈内に新鮮な血栓による閉塞所見を認めた.ここで初めてBudd-Chiari症候群と診断され,加療目的に当院紹介入院となった.ダナパロイドナトリウム2500 U/dayによる治療が行われたが,血栓は改善せず,浮腫・腹水著明となった.肝不全,呼吸不全の進行により,同年2月永眠された.剖検では右及び中肝静脈領域は陳旧性血栓に伴う肝硬変の所見であったが,左肝静脈領域はうっ血性に腫大しており,新鮮な肝静脈血栓を認めた.この所見により,右中肝静脈閉塞が先行し,その後左肝静脈にも血栓が生じたことで,段階的かつ急速に肝不全が進行したことが確認された.Budd-Chiari症候群は希少疾患であるが,今回我々は剖検によって病態の進行過程を確認できた興味深い貴重な症例を経験した.また救命のためには迅速な肝移植が必要であったと思われた.

    • 1 October 2013
      • Vol. 60  (127) , 1557-60

    Drug induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in patient with double positive for HBV and HCV.

    by Hitoshi Takagi, Takashi Hoshino, Atsushi Naganuma, Eri Koitabashi, Sanae Uehara, Naomi Sakamoto, Tomohiro Kudo, Keiichirou Ryusaki, Satoru Kakizaki, Hiroaki Okamoto

    Sixty year-old male positive for both HCV-RNA and HBsAg was treated by triple therapy of peginterferon alpha2b, ribavirin and telaprevir. Eight weeks after the beginning of the therapy, the patient developed drug induced hypersensitivity syndrome (DIHS) with general erythema multiforme and 64 times anti-HHV6 antibody elevation. Sixty milligram of prednisolone was administered with gradual dose reduction and the skin lesion was improved. HBV-DNA and transaminase elevated one week after the steroid induction and entecavir improved them. DIHS itself and the aggravation of hepatitis B by corticosteroid should be kept in mind in cases with dual infection of HBV and HCV treated by antivirals including telaprevir.


    • 1 February 2013
      • Vol. 110  (2) , 263-70

    [A case of so-called carcinosarcoma of the middle portion of the bile duct diagnosed preoperatively].

    by Takashi Hoshino, Atsushi Naganuma, Hitoshi Takagi, Eri Koitabashi, Naomi Sakamoto, Masahiro Inui, Hiromitsu Souma, Tomohiro Kudo, Hiroshi Ishihara, Akira Ogawa, et al.

    A 73-year-old man was admitted to a hospital with a complaint of epigastralgia and for evaluation of liver dysfunction. After hospitalization, he experienced disturbance of consciousness with septic shock, and was then transferred to our hospital. Computed tomography revealed dilatation of the intrahepatic bile duct and tumor of the middle bile duct. We diagnosed acute obstructive suppurative cholangitis. As a result, endoscopic nasobiliary drainage was performed, and the patient recovered. Based on pathological examinations of the bile duct biopsy specimen, the tumor was diagnosed as a carcinosarcoma. Consequently, the patient underwent pylorus-preserving pancreatoduodenectomy. However, 4 months after surgery, the patient died due to widespread metastasis of the carcinosarcoma. Preoperative diagnosis of carcinosarcoma of the bile duct is extremely rare. Our study suggests the efficacy of bile duct biopsy in such cases.


    • 1 December 2012
      • Vol. 32  (12) , 5251-62

    Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.

    by Yoshimi Nakajima, Hitoshi Takagi, Satoru Kakizaki, Norio Horiguchi, Ken Sato, Noriaki Sunaga, Masatomo Mori

    Cholangiocarcinoma (CCC) is the second most common type of primary liver cancer, and is associated with a high rate of mortality due to the difficulty of early detection and resistance to chemotherapeutic agents. To evaluate the possibility for new therapeutic strategies, we examined the combined effect of gefitinib and gemcitabine on CCC. The effect of gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) signaling, gemcitabine, which is a pyrimidine analog, and the combined effect of gefitinib and gemcitabine on CCC cells were evaluated both in vitro and in vivo. EGFR mRNA expression and phosphorylation of EGFR were elevated in both human CCC cell lines studied, HuCCT1 and RBE, suggesting EGFR signaling is up-regulated in CCC cell lines. Gefitinib treatment at high concentration inhibited the proliferation of the CCC cell lines. Furthermore, gefitinib reduced the transforming growth factor alpha (TGFα)-induced proliferation of these cells. Gemcitabine also suppressed the growth of the CCC cell lines in a concentration-dependent manner. The combination of gefitinib and gemcitabine synergistically suppressed the growth of the CCC cell lines and induced greater apoptosis compared to the use of either agent alone. As a mechanism for this effect, we found less phosphorylation of the extracellular signal-regulated kinase (ERK) protein, which means the suppression of EGFR signaling, when these compounds were administered together. Cell transplantation assay dramatically demonstrated the synergistic effect of this combination on HuCCT1 xenografts in vivo. The combination of gefitinib and gemcitabine inhibited the proliferation of CCC cells via induction of apoptosis. The combination of EGFR inhibitor and additional chemicals could be a new therapeutic approach for CCC.


    • 1 April 2012
      • Vol. 109  (4) , 624-9

    [A case of hepatitis E differentially diagnosed from drug-induced liver injury].

    by Sho Ishiwata, Hitoshi Takagi, Takashi Hoshino, Atsushi Naganuma, Naomi Sakamoto, Eri Koitabashi, Hiromitsu Souma, Masayuki Inui, Tomohiro Kudo, Akira Ogawa, et al.

    A woman in her seventies was admitted because of general fatigue and liver dysfunction (ALT 2565 IU/l). She was diabetic and, 2 months ago, began eating kikuimo (Jerusalem artichoke) containing inulin, which is thought to decrease blood sugar level. Although tests showed no evidence of acute infection of HAV, HBV, HCV, EBV and CMV, a drug-induced lymphocyte stimulation test using kikuimo extract was positive. She was first diagnosed with drug-induced liver injury according to the Japanese diagnostic criteria for the disease. After a non-eventful recovery, her serum was found to be positive for hepatitis E-antibody and RNA (genotype 3), indicating recent, autochthonous infection of HEV. The patient might have been misdiagnosed with drug-induced liver injury unless the serum test for HEV had been performed. We believe that HEV screening is mandatory for accurate diagnosis of hepatitis E and drug-induced liver injury.


  • Ruptured hepatocellular carcinoma successfully treated with systemic PEG-IFN and 5FU combination therapy: A case report

    by Yutaka Yata, Masashi Namikawa, Daisuke Kanda, Takeshi Hatanaka, Tatsuya Ohyama, Tamon Nagashima, Jun Kubota, Hitoshi Takagi, Teruo Yoshinaga

    症例は56歳,男性.C型肝硬変に腹膜播種を伴う進行肝細胞癌(HCC)を併発し,ペグインターフェロンα併用5FU全身化学療法(PEG-IFN/5FU全身療法)を施行したところ,化学療法開始直後に出血性ショック状態となった.腹部CT検査で腹腔内出血を確認し,化学療法に伴う肝癌破裂と診断した.保存的加療にて軽快し,かつPEG-IFN/5FU全身療法によりHCCは腹膜播種巣を含め著明に縮小した.このため,PEG-IFN/5FU全身療法を計5コース施行したところ,同療法は奏功した.化学療法に伴うHCC破裂は化学療法が有効であるがゆえに生じる可能性があり,循環動態の安定が得られた後に,同療法を繰り返すことで著効が期待できる.腹膜播種を伴う進行HCCにPEG-IFN/5FU全身療法は考慮すべき治療法と考えられた.


  • Optimal follow‐up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated‐interferon and ribavirin

    by Masashi Namikawa, Satoru Kakizaki, Yutaka Yata, Yuichi Yamazaki, Norio Horiguchi, Ken Sato, Hitoshi Takagi, Masatomo Mori

    Background and Aim: This study evaluated whether the assessment of hepatitis C virus (HCV)-RNA at 12 weeks (FW+12) post-treatment follow-up was as applicable as FW+24 to evaluate sustained virological response (SVR) using the highly sensitive real-time polymerase chain reaction (PCR) HCV assay. Methods and Results: Two hundred and twenty-two patients with chronic hepatitis C were included in this study. Pegylated interferon (Peg-IFN) and ribavirin were administered for 24–72 weeks based on the genotype and viral load. Serum HCV-RNA was measured using real-time PCR at pretreatment, the end of treatment, FW+4, FW+8, FW+12, FW+16, FW+20 and FW+24. Two hundred patients had a virological response at the end of treatment. One hundred and forty-eight of 200 (74.0%) patients with a virological response at the end of treatment had an SVR at the FW+24. The positive predictive value (PPV) to identify patients with SVR at FW+4, FW+8, FW+12 was 87.1, 96.1, 98.0%, respectively. The viral load showed a reversion to the basal level as early as 8 weeks in relapse patients. There were only three patients who relapsed after FW+12 and all three of these patients were females with genotype Ib and a high viral load. Conclusion: The assessment of serum HCV-RNA FW+12, using the highly sensitive real-time PCR assay, is almost as effective as FW+24 to predict SVR. However, there are false negatives in female patients with a high viral load of genotype Ib when the SVR is predicted by FW+12. The current standard with FW+24 is reasonable, but the assessment of serum HCV-RNA FW+12 may be effective in most patients.